Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
GSK2879552 2HCl (1401966-69-5(free base))
Contact us for more batch information
GSK2879552 2HCl (1401966-69-5(free base))
Catalog No. T4418
GSK2879552 is an orally available, irreversible inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $54 | In Stock | |
| 2 mg | $78 | In Stock | |
| 5 mg | $111 | In Stock | |
| 10 mg | $185 | In Stock | |
| 25 mg | $308 | In Stock | |
| 50 mg | $433 | In Stock | |
| 100 mg | $642 | In Stock | |
| 500 mg | $1,370 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $111 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "GSK2879552 2HCl (1401966-69-5(free base))"
CP2
T35338
CP2 is a useful organic compound for research related to life sciences and the catalog number is T35338.
- $221
Size
QTY
GSK467
T54841628332-52-4
GSK467 is a potent and selective inhibitor of KDM5 (JARID1)(Ki : 10 nM).
- $74
Size
QTY
CPI-455 HCl
T222992095432-28-1
CPI-455 is a specific KDM5 inhibitor with IC50 value of 10 ± 1 nM for full-length KDM5A in enzymatic assays, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with target
- $1,520
Size
QTY
YUKA1
T17278708991-09-7
YUKA1 is a potent and cell-permeable Lysine demethylase 5A inhibitor (IC50: 2.66 μM) and less active on KDM5C (IC50, 7.12 μM). YUKA1 is inactive on KDM5B, KDM6A, or KDM6B.
- $1,520
Size
QTY
PBIT
T164352514-30-9
PBIT inhibits JARID1B histone demethylase (IC50 of about 3 μM). PBIT also inhibits JARID1A and JARID1C (IC50s of 6 μM and 4.9 μM, respectively). PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes .
- $34
Size
QTY
T-448 free base
T130561597426-52-2
T-448 free base is a specific, orally active and irreversible lysine-specific demethylase 1 (LSD1, an H3K4 demethylase) inhibitor(IC50 of 22 nM).
- $1,820
Size
QTY
Corin
T108641808113-09-8In house
Corin is an irreversible inhibitor of HDAC1(IC50 = 147 nM) and LSD1(Ki = 110 nM).
- $179
Size
QTY
QC6352
T167001851373-36-8In house
QC6352 is a selective and effective KDM4C inhibitor (IC50: 35 nM).
- $1,520
Size
QTY
Methylstat
T70571310877-95-2
Methylstat is a methyl ester prodrug of a Jumonji C domain-containing histone demethylase (JMJD) inhibitor that has favorable cell permeability. The free acid of methylstat inhibits JMJD2A, JMJD2C, JMJD2E, PHF8, and JMJD3 with IC50 values of approximately 4.3, 3.4, 5.9, 10, and 43 μM, respectively, in an in vitro assay. Methylstat inhibits growth of the JMJD2C-sensitive esophageal cancer cell line KYSE150 with a GI50 of 5.1 μM, whereas the free acid of methylstat did not inhibit cell growth up to 100 μM. Methylstat induces histone hypermethylation at multiple sites in a concentration-dependent manner (EC50 for H3K4me3 and H3K9me3 = 10.3 and 8.6 μM in KYSE150 cells and 6.7 ad 6.3 μM in MCF-7 cells, respectively).
- $199
Size
QTY
L-2-Hydroxyglutaric acid disodium
T1374863512-50-5
L-2-Hydroxyglutaric acid disodium ((S)-2-Hydroxyglutaric acid disodium) is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity(Km and Ki of 2.52 mM and 11.13 mM, respectively).
- $45
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | GSK2879552 is an orally available, irreversible inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. |
| In vitro | GSK2879552 inhibits KDM1A histone demethylase activity, inducing differentiation of sorafenib-resistant cells and attenuates stemness properties. GSK2879552 derepresses the transcription of Wnt antagonists and downregulates β-catenin signaling activity in sorafenib-resistant cells[1]. GSK2879552 is 280-fold selective over D-amino acid oxidase, allowing for direct comparison of inactivation efficiency (KIapp=520 ± 170 μM, kinact=0.12 ± 0.01 min?1, kinact/KIapp=2.3×10-4 ± 1.31×10-5 min-1 μM-1). GSK2879552 inhibits the growth of 9/28 small cell lung carcinoma (SCLC) lines and 20/29 AML lines, with EC50 of 2-240 nM |
| In vivo | GSK2879552 (1.5 mg/kg, p.o.) treatment exhibits tumor growth inhibition in SCLC xenograft bearing mice. There is 57% and 83% tumor growth inhibition (TGI) in NCI-H526 and NCI-H1417 tumor bearing mice respectively. NCI-H510 and NCI-H69 tumor bearing mice also demonstrate partial TGI (38% and 49% respectively) in response to GSK2879552, while no significant TGI is observed for SHP77 bearing mice |
| Cell Research | Viable cells are measured in Cell Counting Kit-8 (CCK8) assay. Briefly, cells are cultured in a 96-well plate overnight at a density of 5×103 cells per well and treated with the indicated concentrations of sorafenib (0 μM, 40 μM or 80 μM) for 24 h. Subsequently, the cells are incubated with 10 μL CCK8 for 60 min at 37°C, 5% CO2. The absorbance of optical density at 450 nm (A450) is determined with Varioskan Flash. |
| Molecular Weight | 437.41 |
| Formula | C23H30Cl2N2O2 |
| Cas No. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||
| Solubility Information | DMSO: 4.37 mg/mL (10 mM) | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
| ||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.